Interaction of developmental transcription factor HOX11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1585-1594

  McIlroy, Marie ^a   McCartan, Damian ^a   Early, Sarah ^a   Gaora, Peadar Ó ^b   Pennington, Stephen ^b   Hill, Arnold D K ^a   Young, Leonie S ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN S100B; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOX11; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL STRAIN MCF 7; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOLECULAR INTERACTION; MULTIMODALITY CANCER THERAPY; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; RISK ASSESSMENT; TISSUE MICROARRAY; TUMOR BIOPSY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, DEVELOPMENTAL; HOMEODOMAIN PROTEINS; HUMANS; NERVE GROWTH FACTORS; NUCLEAR RECEPTOR COACTIVATOR 1; PROGNOSIS; PROTEIN BINDING; S100 PROTEINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 76749167060     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3713     Document Type: Article

References (24)

1. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
2. Redmond AM, Bane FT, Stafford AT, et al. Coassociation 1 of ER and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 2009;15:2098-106.
3. Wang S, Yuan Y, Liao L, et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis. PNAS 2009;106:151-6.
4. Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 2009;279:14909-16.
5. Myers E, Hill AD, Kelly G, et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005;11:2111-22.
6. Qin L, Liao L, Redmond A, et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 2008;28: 5937-50.
7. Al-azawi D, Ilroy MM, Kelly G, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008;27:3021-31.
8. Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 2009;69:3819-27.
9. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985;117:1409-17.
10. Myers E, Fleming FJ, Crotty TB, et al. Inverse relationship between ER-βand SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 2004;91:1687-93.
11. Zhang X, Hamada J, Nishimoto A, Takahashi Y, Murai T, Tada M, Moriuchi T. HOXC6 and HOXC11 increase transcription of S100β gene in BrdU-induced in vitro differentiation of GOTO neuroblastoma cells into Schwannian cells. J Cell Mol Med 2007;11:299-306.
12. Dillon MF, Stafford AT, Kelly G, et al. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer 2008; 15:745-53.
13. Miller GJ, Miller HL, van Bokhoven A, et al. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 2003;63:5879-88.
14. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
15. Dudek P, Picard D. Genomics of signaling crosstalk of estrogen receptor α in breast cancer cells. PLoS ONE 2008;3:e1859.
16. Svingen T, Tonissen KF. Hox transcription factors and their elusive mammalian gene targets. Heredity 2006;97:88-96.
17. Donato R, Sorci G, Riuzzi F, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009;3: 1008-22.
18. Hergovich A, Stegert MR, Schmitz D, Hemmings BA. NDR kinases regulate essential cell processes at yeast to humans. Nat Rev Mol Cell Biol 2006;7:253-64.
19. Markowitz J, MacKerell AD, Jr., Weber DJ. A search for inhibitors of S100β a member of the S100 family of calcium binding proteins. Mini Rev Med Chem 2007;7:609-16.
20. Makiyama K, Hamada J, Takada M, et al. Aberrant expression of HOX genes in human invasive carcinoma. Oncol Rep 2005;13:673-9.
21. Mohankumar KM, Xu XQ, Zhu T, et al. HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene 2007;26:3998-4008.
22. Schmidt H, Sorensen BS, Nexo E, von der Maase H. S100βprotein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. Melanoma Res 2004;14:211-5.
23. Mohammed MQ, Abraha HD, Sherwood RA, MacRae K, Retsas S. Serum S100βprotein as a marker of disease activity in patients with malignant melanoma. Med Oncol 2001;18:109-20.
24. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100β in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008;123:2370-76.